Limits...
miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases.

Xu Q, Li P, Chen X, Zong L, Jiang Z, Nan L, Lei J, Duan W, Zhang D, Li X, Sha H, Wu Z, Ma Q, Wang Z - Oncotarget (2015)

Bottom Line: MicroRNAs are involved in the initiation and progression of pancreatic cancer.MiR-221/222 overexpression significantly promoted pancreatic cancer cell proliferation and invasion while inhibiting apoptosis.These data indicate that overexpressed miR-221/222 may play an oncogenic role in pancreatic cancer by inducing the expression of MMP-2 and MMP-9, thus leading to cancer cell invasion.

View Article: PubMed Central - PubMed

Affiliation: Department of Hepatobiliary Surgery, First Affiliated Hospital Medical College of Xi'an Jiaotong University, Xi'an, Shaanxi, China.

ABSTRACT
MicroRNAs are involved in the initiation and progression of pancreatic cancer. In this study, we showed that miR-221/222 is overexpressed in pancreatic cancer. MiR-221/222 overexpression significantly promoted pancreatic cancer cell proliferation and invasion while inhibiting apoptosis. The expression of the matrix metalloproteinases (MMPs) MMP-2 and MMP-9 was increased in miR-221/222 mimic-transfected pancreatic cancer cells. Validation experiments identified TIMP-2 as a direct target of miR-221/222. These data indicate that overexpressed miR-221/222 may play an oncogenic role in pancreatic cancer by inducing the expression of MMP-2 and MMP-9, thus leading to cancer cell invasion.

No MeSH data available.


Related in: MedlinePlus

Up-regulated or down-regulated miR-221/222 levels in pancreatic cancer cell lines induce growth promotion and inhibition(A) The MTT assay showed growth promotion or inhibition in Panc-1 and SW-1990 cells transfected with various concentrations of miR-221/222 mimics or inhibitors. At 48 h after transfection, the growth inhibition in Panc-1 cells transfected with miR-221/222 inhibitors was 64.65 ± 10.47% and 71.73 ± 8.10%. Similarly, SW-1990 cells showed 67.25 ± 12.23% and 57.20 ± 12.45% decreases by reducing miR-221/222 levels. Growth promotion in Panc-1 cells transfected with miR-221/222 mimics was 129.68 ± 7.24% and 134.06 ± 10.33%. Similarly, SW-1990 cells showed 135.63 ± 8.50% and 135.35 ± 12.13% increases in growth by enhancing miR-221/222 levels. (B) The MTT assay showed growth promotion or inhibition in Panc-1 and SW-1990 cells transfected with miR-221/222 mimics or inhibitors at different time points.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4546457&req=5

Figure 2: Up-regulated or down-regulated miR-221/222 levels in pancreatic cancer cell lines induce growth promotion and inhibition(A) The MTT assay showed growth promotion or inhibition in Panc-1 and SW-1990 cells transfected with various concentrations of miR-221/222 mimics or inhibitors. At 48 h after transfection, the growth inhibition in Panc-1 cells transfected with miR-221/222 inhibitors was 64.65 ± 10.47% and 71.73 ± 8.10%. Similarly, SW-1990 cells showed 67.25 ± 12.23% and 57.20 ± 12.45% decreases by reducing miR-221/222 levels. Growth promotion in Panc-1 cells transfected with miR-221/222 mimics was 129.68 ± 7.24% and 134.06 ± 10.33%. Similarly, SW-1990 cells showed 135.63 ± 8.50% and 135.35 ± 12.13% increases in growth by enhancing miR-221/222 levels. (B) The MTT assay showed growth promotion or inhibition in Panc-1 and SW-1990 cells transfected with miR-221/222 mimics or inhibitors at different time points.

Mentions: To investigate the influence of miR-221/222 on cell proliferation, the MTT assay was used. MTT assays (both dose-dependent and time-dependent) illustrated significant increases or decreases in Panc-1 and SW-1990 cells after transfection of miR-221/222 mimics or miR-221/222 inhibitors, respectively (Figure 2). At 48 h after transfection, Panc-1 and SW-1990 cells were significantly inhibited when transfected with miR-221/222, and the maximum growth inhibition appeared at 48 h after transfection (p < 0.05) compared with the miRNA mimics.


miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases.

Xu Q, Li P, Chen X, Zong L, Jiang Z, Nan L, Lei J, Duan W, Zhang D, Li X, Sha H, Wu Z, Ma Q, Wang Z - Oncotarget (2015)

Up-regulated or down-regulated miR-221/222 levels in pancreatic cancer cell lines induce growth promotion and inhibition(A) The MTT assay showed growth promotion or inhibition in Panc-1 and SW-1990 cells transfected with various concentrations of miR-221/222 mimics or inhibitors. At 48 h after transfection, the growth inhibition in Panc-1 cells transfected with miR-221/222 inhibitors was 64.65 ± 10.47% and 71.73 ± 8.10%. Similarly, SW-1990 cells showed 67.25 ± 12.23% and 57.20 ± 12.45% decreases by reducing miR-221/222 levels. Growth promotion in Panc-1 cells transfected with miR-221/222 mimics was 129.68 ± 7.24% and 134.06 ± 10.33%. Similarly, SW-1990 cells showed 135.63 ± 8.50% and 135.35 ± 12.13% increases in growth by enhancing miR-221/222 levels. (B) The MTT assay showed growth promotion or inhibition in Panc-1 and SW-1990 cells transfected with miR-221/222 mimics or inhibitors at different time points.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4546457&req=5

Figure 2: Up-regulated or down-regulated miR-221/222 levels in pancreatic cancer cell lines induce growth promotion and inhibition(A) The MTT assay showed growth promotion or inhibition in Panc-1 and SW-1990 cells transfected with various concentrations of miR-221/222 mimics or inhibitors. At 48 h after transfection, the growth inhibition in Panc-1 cells transfected with miR-221/222 inhibitors was 64.65 ± 10.47% and 71.73 ± 8.10%. Similarly, SW-1990 cells showed 67.25 ± 12.23% and 57.20 ± 12.45% decreases by reducing miR-221/222 levels. Growth promotion in Panc-1 cells transfected with miR-221/222 mimics was 129.68 ± 7.24% and 134.06 ± 10.33%. Similarly, SW-1990 cells showed 135.63 ± 8.50% and 135.35 ± 12.13% increases in growth by enhancing miR-221/222 levels. (B) The MTT assay showed growth promotion or inhibition in Panc-1 and SW-1990 cells transfected with miR-221/222 mimics or inhibitors at different time points.
Mentions: To investigate the influence of miR-221/222 on cell proliferation, the MTT assay was used. MTT assays (both dose-dependent and time-dependent) illustrated significant increases or decreases in Panc-1 and SW-1990 cells after transfection of miR-221/222 mimics or miR-221/222 inhibitors, respectively (Figure 2). At 48 h after transfection, Panc-1 and SW-1990 cells were significantly inhibited when transfected with miR-221/222, and the maximum growth inhibition appeared at 48 h after transfection (p < 0.05) compared with the miRNA mimics.

Bottom Line: MicroRNAs are involved in the initiation and progression of pancreatic cancer.MiR-221/222 overexpression significantly promoted pancreatic cancer cell proliferation and invasion while inhibiting apoptosis.These data indicate that overexpressed miR-221/222 may play an oncogenic role in pancreatic cancer by inducing the expression of MMP-2 and MMP-9, thus leading to cancer cell invasion.

View Article: PubMed Central - PubMed

Affiliation: Department of Hepatobiliary Surgery, First Affiliated Hospital Medical College of Xi'an Jiaotong University, Xi'an, Shaanxi, China.

ABSTRACT
MicroRNAs are involved in the initiation and progression of pancreatic cancer. In this study, we showed that miR-221/222 is overexpressed in pancreatic cancer. MiR-221/222 overexpression significantly promoted pancreatic cancer cell proliferation and invasion while inhibiting apoptosis. The expression of the matrix metalloproteinases (MMPs) MMP-2 and MMP-9 was increased in miR-221/222 mimic-transfected pancreatic cancer cells. Validation experiments identified TIMP-2 as a direct target of miR-221/222. These data indicate that overexpressed miR-221/222 may play an oncogenic role in pancreatic cancer by inducing the expression of MMP-2 and MMP-9, thus leading to cancer cell invasion.

No MeSH data available.


Related in: MedlinePlus